Serum chitotriosidase: a circulating biomarker in polycythemia vera

References

• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi: 10.1038/nature03546
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779–1790. doi: 10.1056/NEJMoa051113
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387–397. doi: 10.1016/j.ccr.2005.03.023
   PubMed Web of Science ®Google Scholar
• Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198–4200. doi: 10.1182/blood-2003-10-3471
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472–3476. doi: 10.1182/blood-2006-04-018879
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–2390. doi: 10.1056/NEJMoa1311347
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–2405. doi: 10.1056/NEJMoa1312542
   PubMed Web of Science ®Google Scholar
• Skoda RC, Duek A, Grisouard J. Pathogenesis of myeloproliferative neoplasms. Exp Hematol. 2015;43(8):599–608. doi: 10.1016/j.exphem.2015.06.007
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225. doi: 10.1182/blood-2011-11-394775
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Bjørn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476. doi: 10.1155/2015/102476
   PubMed Web of Science ®Google Scholar
• Geyer HL, Dueck AC, Scherber MR. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm. 2015;2015:284706. doi: 10.1155/2015/284706
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN landmark survey. BMC Cancer. 2016;16(1):211. doi: 10.1186/s12885-016-2208-2
   PubMedGoogle Scholar
• Fleischman AG, Aichberger KJ, Luty SB, et al. TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011;118(24):6392–6398. doi: 10.1182/blood-2011-04-348144
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–1363. doi: 10.1200/JCO.2010.32.9490
   PubMed Web of Science ®Google Scholar
• Vaidya R, Gangat N, Jimma T, et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87(11):1003–1005. doi: 10.1002/ajh.23295
   PubMed Web of Science ®Google Scholar
• Pourcelot E, Trocme C, Mondet J, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–368. doi: 10.1016/j.exphem.2014.01.006
   PubMed Web of Science ®Google Scholar
• Zahr AA, Salama ME, Carreau N, et al. Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies. Haematologica. 2016;101(6):660–671. doi: 10.3324/haematol.2015.141283
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807. doi: 10.1056/NEJMoa1110557
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–798. doi: 10.1056/NEJMoa1110556
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117–1127. doi: 10.1056/NEJMoa1002028
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–520. doi: 10.1002/cncr.28441
   PubMed Web of Science ®Google Scholar
• Agarwal A, Morrone K, Bartenstein M, et al. Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β. Stem Cell Investig. 2016;3:5.
   PubMedGoogle Scholar
• Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood. 2008;112(3):470–478. doi: 10.1182/blood-2008-03-077883
   PubMed Web of Science ®Google Scholar
• Soni S, Bala S, Gwynn B, et al. Absence of erythroblast macrophage protein (Emp) leads to failure of erythroblast nuclear extrusion. J Biol Chem. 2006;281(29):20181–20189. doi: 10.1074/jbc.M603226200
   PubMed Web of Science ®Google Scholar
• Yoshida H, Kawane K, Koike M, et al. Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells. Nature. 2005;437(7059):754–758. doi: 10.1038/nature03964
   PubMed Web of Science ®Google Scholar
• Seki M, Shirasawa H. Role of the reticular cells during maturation process of the erythroblast. 3. The fate of phagocytized nucleus. Acta Pathol Jpn. 1965;15:387–405.
   PubMedGoogle Scholar
• Sadahira Y, Yasuda T, Yoshino T, et al. Impaired splenic erythropoiesis in phlebotomized mice injected with CL2MDP-liposome: an experimental model for studying the role of stromal macrophages in erythropoiesis. J Leukoc Biol. 2000;68(4):464–470.
   PubMed Web of Science ®Google Scholar
• Hanspal M, Hanspal JS. The association of erythroblasts with macrophages promotes erythroid proliferation and maturation: a 30-kD heparin-binding protein is involved in this contact. Blood. 1994;84(10):3494–3504.
   PubMed Web of Science ®Google Scholar
• Rhodes MM, Kopsombut P, Bondurant MC, et al. Adherence to macrophages in erythroblastic islands enhances erythroblast proliferation and increases erythrocyte production by a different mechanism than erythropoietin. Blood. 2007;111(3):1700–1708. doi: 10.1182/blood-2007-06-098178
   PubMed Web of Science ®Google Scholar
• Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia. Nat Med. 2013;19(4):437–445. doi: 10.1038/nm.3126
   PubMed Web of Science ®Google Scholar
• Boot RG, Renkema GH, Verhock M, et al. The human chitotriosidase gene. J Biol Chem. 1998;273(40):25680–25685. doi: 10.1074/jbc.273.40.25680
   PubMed Web of Science ®Google Scholar
• Kzhyshkowska J, Gratchev A, Goerdt S. Human chitinases and chitinase-like proteins as indicators for inflammation and cancer. Biomark Insights. 2007;2:128–146. doi: 10.1177/117727190700200023
   PubMedGoogle Scholar
• Malaguarnera L. Chitotriosidase: the yin and yang. Cell Mol Life Sci. 2006;63(24):3018–3029. doi: 10.1007/s00018-006-6269-2
   PubMed Web of Science ®Google Scholar
• Van Eijk M, Van Roomen CP, Renkema GH, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol. 2005;17(11):1505–1512. doi: 10.1093/intimm/dxh328
   PubMed Web of Science ®Google Scholar
• Labadaridis I, Dimitriou E, Theodorakis M, et al. Chitotriosidase in neonates with fungal and bacterial infections. Arch Dis Child Fetal Neonatal Ed. 2005;90(6):F531–F532. doi: 10.1136/adc.2004.051284
   PubMed Web of Science ®Google Scholar
• Choi EH, Zimmerman PA, Foster CB, et al. Genetic polymorphisms in molecules of innate immunity and susceptibility to infection with Wuchereria bancrofti in south india. Genes Immun. 2001;2(5):248–253. doi: 10.1038/sj.gene.6363767
   PubMed Web of Science ®Google Scholar
• Malaguarnera L, Simpore J, Prodi DA, et al. A 24-bp duplication in exon 10 of human chitotriosidase gene from the sub-Saharan to the Mediterranean area: role of parasitic diseases and environmental conditions. Genes Immun. 2003;4(8):570–574. doi: 10.1038/sj.gene.6364025
   PubMed Web of Science ®Google Scholar
• Malaguarnera L, Musumeci M, Di Rosa M, et al. Interferon-gamma, tumor necrosis factor-alpha, and lipopolysaccharide promote chitotriosidase gene expression in human macrophages. J Clin Lab Anal. 2005;19(3):128–132. doi: 10.1002/jcla.20063
   PubMed Web of Science ®Google Scholar
• Van Eijk M, Scheij SS, Van Roomen CP, et al. TLR- and NOD2-dependent regulation of human phagocyte-specific chitotriosidase. FEBS Lett. 2007;581(28):5389–5395. doi: 10.1016/j.febslet.2007.10.039
   PubMed Web of Science ®Google Scholar
• Hollak CE, Weely SV, Oers MHV, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994;93(3):1288–1292. doi: 10.1172/JCI117084
   PubMed Web of Science ®Google Scholar
• Aerts JM, Hollak CE. 4 plasma and metabolic abnormalities in Gaucher’s disease. Baillieres Clin Haematol. 1997;10(4):691–709. doi: 10.1016/S0950-3536(97)80034-0
   PubMedGoogle Scholar
• Barone R, Di Gregorio F, Romeo MA, et al. Plasma chitotriosidase activity in patients with β-thalassemia. Blood Cells Mol Dis. 1999;25(1):1–8. doi: 10.1006/bcmd.1999.0221
   PubMed Web of Science ®Google Scholar
• Musumeci M, Caruso V, Medulla E, et al. Serum YKL-40 levels and chitotriosidase activity in patients with beta-thalassemia major. Dis Markers. 2014;2014:965971. doi: 10.1155/2014/965971
   PubMedGoogle Scholar
• Barone R, Simpore J, Malaguarnera L, et al. Plasma chitotriosidase activity in acute plasmodium falciparum malaria. Clin Chim Acta. 2003;331(1–2):79–85. doi: 10.1016/S0009-8981(03)00089-5
   PubMed Web of Science ®Google Scholar
• Bargagli E, Bianchi N, Margollicci M, et al. Chitotriosidase and soluble IL-2 receptor: comparison of two markers of sarcoidosis severity. Scand J Clin Invest. 2008;68(6):479–483. doi: 10.1080/00365510701854975
   PubMed Web of Science ®Google Scholar
• Boot RG, Hollak CEM, Verhoek M, et al. Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. Clin Chim Acta. 2010;411(1–2):31–36. doi: 10.1016/j.cca.2009.09.034
   PubMed Web of Science ®Google Scholar
• Popevic S, Sumarac Z, Jovanovic D, et al. Verifying sarcoidosis activity: chitotriosidase versus ACE in sarcoidosis-A case-control study-. J Med Biochem. 2016;35(4):390–400. doi: 10.1515/jomb-2016-0017
   PubMed Web of Science ®Google Scholar
• Koening CL, Gota C, Langford CA, et al. Serum chitotriosidase activity and Wegener’s granulomatosis. Clin Biochem. 2010;43(4–5):512–514. doi: 10.1016/j.clinbiochem.2009.11.015
   PubMed Web of Science ®Google Scholar
• Malaguarnera L, Rosa MD, Zambito AM, et al. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut. 2006;55(9):1313–1320. doi: 10.1136/gut.2005.075697
   PubMed Web of Science ®Google Scholar
• Létuvé S, Kozhich A, Humbles A, et al. Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol. 2010;176(2):638–649. doi: 10.2353/ajpath.2010.090455
   PubMed Web of Science ®Google Scholar
• Lee CG, Herzog EL, Ahangari F, et al. Chitinase 1 Is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF- 1 signaling. J Immunol. 2012;189(5):2635–2644. doi: 10.4049/jimmunol.1201115
   PubMed Web of Science ®Google Scholar
• Karadag B, Kucur M, Isman FK, et al. Serum chitotriosidase activity in patients with coronary artery disease. Circ J. 2008;72(1):71–75. doi: 10.1253/circj.72.71
   PubMed Web of Science ®Google Scholar
• Artieda M, Cenarro A, Ganan A, et al. Serum chitotriosidase activity is increased in subjects with atherosclerosis disease. Arterioscler Thromb Vasc Biol. 2003;23(9):1645–1652. doi: 10.1161/01.ATV.0000089329.09061.07
   PubMed Web of Science ®Google Scholar
• Yildiz BS, Barutcuoglu B, Alihanoglu YI, et al. Serum chitotriosidase activity in acute coronary syndrome. J Atheroscler Thromb. 2013;20(2):134–141. doi: 10.5551/jat.13920
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the world health organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951. doi: 10.1182/blood-2009-03-209262
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia. 2008;22(2):437–438. doi: 10.1038/sj.leu.2404914
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–1132.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Arnalich F, Lahoz C, Larrocha C, et al. Incidence and clinical significance of peripheral and bone marrow basophilia. J Med. 1987;18(5–6):293–303.
   PubMedGoogle Scholar
• Agis H, Krauth M-T, Mosberger I, et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol. 2006;59(4):396–402. doi: 10.1136/jcp.2005.029215
   PubMed Web of Science ®Google Scholar
• Pieri L, Bogani C, Guglielmelli P, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009;94(11):1537–1545. doi: 10.3324/haematol.2009.007047
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Livun A, Stoos-Veic T, et al. High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis. Hematology. 2017;14:1–7.
   Google Scholar
• Schroeder JT, MacGlashan DW Jr, Lichtenstein LM. Human basophils: mediator release and cytokine production. Adv Immunol. 2001;77:93–122. doi: 10.1016/S0065-2776(01)77015-0
   PubMed Web of Science ®Google Scholar
• Stone KD, Prussin C, Metcalfe DD. Ige, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73–S80. doi: 10.1016/j.jaci.2009.11.017
   PubMed Web of Science ®Google Scholar
• Valent P, Bettelheim P. The human basophil. Crit Rev Oncol/Hematol. 1990;10(4):327–352. doi: 10.1016/1040-8428(90)90009-H
   PubMed Web of Science ®Google Scholar
• Suganuma M, Okabe S, Marino MW, et al. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 1999;59(18):4516–4518.
   PubMed Web of Science ®Google Scholar
• Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29(11):1275–1288. doi: 10.1111/j.1745-7254.2008.00889.x
   PubMed Web of Science ®Google Scholar
• Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med. 1999;5(7):828–831. doi: 10.1038/10552
   PubMed Web of Science ®Google Scholar
• Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008;118(2):560–570.
   PubMed Web of Science ®Google Scholar
• Matthews N, Watkins JF. Tumour-necrosis factor from the rabbit. I. Mode of action, specificity and physicochemical properties. Br J Cancer. 1978;38(2):302–309. doi: 10.1038/bjc.1978.202
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119(10):2239–2241. doi: 10.1182/blood-2011-11-393819
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Barraco D, De Marchi F, et al. Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. Ann Hematol. 2015;94(5):873–874. doi: 10.1007/s00277-014-2257-z
   PubMed Web of Science ®Google Scholar
• Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5(11):e366. doi: 10.1038/bcj.2015.95
   PubMed Web of Science ®Google Scholar
• Bjørn ME, Andersen CL, Jensen MK, et al. Circulating YKL-40 in myelofibrosis a potential novel biomarker of disease activity and the inflammatory state. Eur J Haematol. 2014;93(3):224–228. doi: 10.1111/ejh.12332
   PubMed Web of Science ®Google Scholar
• Andersen CL, Bjørn ME, McMullin MF, et al. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leuk Res. 2014;38(7):816–821. doi: 10.1016/j.leukres.2014.04.002
   PubMed Web of Science ®Google Scholar
• Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol. 2009;5(7):1065–1082. doi: 10.2217/fon.09.66
   PubMed Web of Science ®Google Scholar
• Kazakova MH, Sarafian VS. YKL-40--a novel biomarker in clinical practice? Folia Med Plovdiv. 2009;51(1):5–14.
   PubMedGoogle Scholar
• Sutherland TE, Maizels RM, Allen JE. Chitinases and chitinase-like proteins: potential therapeutic targets for the treatment of T-helper type 2 allergies. Clin Exp Allergy. 2009;39(7):943–955. doi: 10.1111/j.1365-2222.2009.03243.x
   PubMed Web of Science ®Google Scholar
• Galleti G, Scielzo C, Barbaglio F, et al. Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression. Cell Rep. 2016; 23;14(7):1748–1760. doi: 10.1016/j.celrep.2016.01.042
   PubMed Web of Science ®Google Scholar
• Delforge M, Devos T, Rowe J, et al. Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial. Leuk Lymphoma. 2016;57(2):470–473. doi: 10.3109/10428194.2015.1055481
   PubMed Web of Science ®Google Scholar
• Sakai M, Kobori S, Matsumura T, et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 1997;133(1):51–59. doi: 10.1016/S0021-9150(97)00118-4
   PubMed Web of Science ®Google Scholar
• Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 1993;101(1):117–125. doi: 10.1016/0021-9150(93)90107-6
   PubMed Web of Science ®Google Scholar
• Croons V, De Meyer I, Houten SM, et al. Effect of statins on the viability of macrophages and smooth muscle cells. J Cardiovasc Pharmacol. 2010;55(3):269–275. doi: 10.1097/FJC.0b013e3181d0bec3
   PubMed Web of Science ®Google Scholar
• Liang SL, Liu H, Zhou A. Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway. J Immunol. 2006;177(1):651–656. doi: 10.4049/jimmunol.177.1.651
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Riley CH. Statins in the treatment of polycythaemia vera and allied disorders: an antithrombotic and cytoreductive potential? Leuk Res. 2006;30(10):1217–1225. doi: 10.1016/j.leukres.2005.12.018
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck RD, Powles RL, et al. Selective inhibition of primary acute myeloid leukaemia cell growth by simvastatin. Leukemia. 1994;8(11):2023–2029.
   PubMed Web of Science ®Google Scholar
• Newman A, Clutterbuck RD, Powles RL, et al. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitors simvastatin, lovastatin, and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997;24(5–6):533–537. doi: 10.3109/10428199709055590
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999;93(4):1308–1318.
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Thai S, Wasfy GH, et al. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma. 2000;40(1):167–178. doi: 10.3109/10428190009054894
   PubMed Web of Science ®Google Scholar
• Griner LN, McGraw KL, Johnson JO, et al. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol. 2013;160(2):177–187. doi: 10.1111/bjh.12103
   PubMed Web of Science ®Google Scholar
• Sørensen AE, Kallenbach K, Hasselbalch HC. A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate. Leuk Res Rep. 2016;6:20–23.
   PubMedGoogle Scholar